Stay Up to Date on The Latest COVID-19 Data Tracking & Trends

​Wells Health Group is a Health Policy Consulting and Government Relations Firm Based in Washington D.C. 

WHG Helps Clients Navigate the Unprecedented Number of New Federal Emergency Regulations - The COVID-19 Reality & Beyond
Picture
Wells Health Group Areas of Expertise
Health Policy Consulting
Government Relations
M&A Consulting

COVID-19 Reality - New Federal Regulations - Post Outbreak & Beyond

  • New CMS reimbursement pathways in aggregate with the newly formed Technology Coding and Pricing Group to allow for faster access to innovative technologies.
  • New FDA Emergency Use Authorization (EUA) regulations to allow for unapproved medical products or unapproved uses of approved medical products to be used in an emergency.
  • New CDC public health guidance, evolving as the knowledge base grows, and expanded/refined data reporting.
  • New NIH infectious disease research and expanded medical and behavioral health research.

Post Pandemic Impact on the CY 2021 Physician Fee Schedule Update

CY 2021 Physician Fee Schedule Update
  • On December 27, the Consolidated Appropriations Act, 2021 modified the Calendar Year (CY) 2021 Medicare Physician Fee Schedule (MPFS):
  • Provided a 3.75% increase in MPFS payments for CY 2021
  • Suspended the 2% payment adjustment (sequestration) through March 31, 2021
  • Reinstated the 1.0 floor on the work Geographic Practice Cost Index through CY 2023
  • Delayed implementation of the inherent complexity add-on code for evaluation and management services (G2211) until CY 2024
  • CMS has recalculated the MPFS payment rates and conversion factor to reflect these changes. The revised MPFS conversion factor for CY 2021 is 34.8931 down from CY 2020 of 36.0896, a -3.3% reduction.

Wells Health Group - Innovators in Health Policy & Government Relations

WHG's innovative approach to health policy consulting and government relations is built on a two-step sequential process founded on 70+ years successful healthcare industry and government relations experience:
  1. A core set of essential strategy analytics - deep dive into the client’s requirements and an analysis of supporting data to develop executable solutions
  2. Focused reimbursement pathways - evidence based and data driven
Post pandemic outbreak - Federal Agencies, Congress and the Administration require more and more decision-making to be made based upon clinical data evidence – the science supporting the decision.
WHG's two-step process remains the successful foundation of our innovative approach to health policy consulting and government relations - clinical data evidence. Our proven processes helps us collaborate with clients to more effectively navigate all the new emergency use federal regulations.

​​Why Our 70+ Years Industry & Government Relations Experience Matters

  • Because ​we come from the healthcare industry - WHG is uniquely positioned to best understand our client’s challenges and develop targeted government relations’ strategies.
  • Because of our government relations experience representing industry we knew it was critical for WHG to have a Washington D.C. presence.
  • Because WHG is strategically located on Pennsylvania Avenue between the Capitol and the White House and just six blocks for the main HHS building, WHG has been able to more readily access face-to-face meetings at multiple levels of the HHS Agencies and on Capitol Hill.
  • Because of WHG's previous years of Washington D.C. presence, participating in face-to-face meetings at multiple levels of  the HHS Agencies and on Capitol Hill, we are a known entity and know how to leverage  virtual access  to multiple levels of the HHS Agencies and on Capitol Hill.​​
  • Because of WHG’s years of healthcare and government relations experience we understand how to acclimatize and manage the challenge of evolving political ideology and the potential impact on the healthcare delivery system.
Federal Regulations - CMS reimbursement processes, CDC guidance, FDA regulations and NIH expanded research
are not intuitive and can lead to uncertainties and market access complications especially during the HHS Emergency Use Authorization (EUA) Authority